OMA Guidelines Bundle

Obesity Pharmacological Management - OMA Obesity 2021

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/1349812

Contents of this Issue

Navigation

Page 1 of 21

2 Concomitant Medications Key Points   ➤ In 2017 – 2018, the prevalence of obesity was estimated to be ~42% in U.S. adults (≥20 years of age) and ~18.5% of youths (2−19 years of age).   ➤ According to a projection analysis in 2019, ~50% of US adults will have obesity by 2030, with ~25% of adults having severe obesity [body mass index (BMI) ≥35 kg/m 2 ].   ➤ With the exception of anti-obesity agents that are a combination of drugs in a single tablet or capsule, limited data exists for combination anti-obesity drug therapy.   ➤ Targets of current anti-obesity drug development are mainly focused on intervention pathways related to the central nervous system, gastrointestinal systems and adipose tissue. Objectives of Anti-Obesity Medications Improve the health of patients   ➤ Improve hyperglycemia, high blood pressure, and abnormal lipid levels   ➤ Reduce cardiovascular events   ➤ Improve other adverse metabolic, biomechanical, and psychosocial health consequences, with improved quality of life.   ➤ Reduce mortality Improve the weight of patients   ➤ Weight loss to a clinically meaningful degree that patients and clinicians will embrace initiation of anti-obesity therapy   ➤ Weight loss maintenance to a degree that patients and clinicians will persist in adhering to long-term anti-obesity therapy

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacological Management - OMA Obesity 2021